PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance

U.S. Markets close in 1 hr 58 mins

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
33.88+0.14 (+0.43%)
As of 2:02PM EDT. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close33.74
Bid0.00 x
Ask0.00 x
Day's Range33.71 - 33.96
52 Week Range29.83 - 37.39
Avg. Volume23,642,706
Market Cap201.79B
PE Ratio (TTM)28.89
Earnings DateN/A
Dividend & Yield1.28 (3.76%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia1 hour ago

    Chill Pill: Eli Lilly Cuts Guidance with Earnings

    Lilly trimmed its full-year GAAP EPS guidance, dragging shares lower today.

  • 3 Reasons Pfizer Is a Better Dividend Stock Than Bristol-Myers Squibb
    Motley Fool6 hours ago

    3 Reasons Pfizer Is a Better Dividend Stock Than Bristol-Myers Squibb

    Bristol-Myers Squibb might have fast-growing cancer drug Opdivo, but here's why Pfizer is the better dividend stock.

  • PR Newswire6 hours ago

    Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease

    CAMBRIDGE, Mass., April 25, 2017 /PRNewswire/ -- Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced today that two additional pharmaceutical companies, Pfizer Inc. (PFE) and AbbVie Inc. (ABBV), have invested in Aquinnah's work to treat ALS (Amyotrophic Lateral Sclerosis), Alzheimer's disease and other neurodegenerative diseases. This $10 million adds to an earlier $5 million investment made by Takeda Pharmaceuticals in December 2015. "We are excited to have the support of three world-class pharmaceutical companies to expand our drug development efforts from ALS into new RNA binding proteins known to modulate Tau, one of the hallmark pathological proteins involved in Alzheimer's disease," said Glenn Larsen, Ph.D., Aquinnah's President and Chief Executive Officer.